Algert Global LLC continued to hold its position in Harvard Bioscience, Inc. (NASDAQ:HBIO) during the second quarter, Holdings Channel reports. The institutional investor owned 113,818 shares of the medical instruments supplier’s stock at the end of the second quarter. Algert Global LLC’s holdings in Harvard Bioscience were worth $290,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Essex Investment Management Co. LLC boosted its position in Harvard Bioscience by 38.7% in the second quarter. Essex Investment Management Co. LLC now owns 429,460 shares of the medical instruments supplier’s stock worth $1,095,000 after buying an additional 119,878 shares during the last quarter. Heartland Advisors Inc. boosted its position in Harvard Bioscience by 5.0% in the first quarter. Heartland Advisors Inc. now owns 2,100,000 shares of the medical instruments supplier’s stock worth $5,460,000 after buying an additional 100,000 shares during the last quarter. Royce & Associates LP boosted its position in Harvard Bioscience by 2.9% in the first quarter. Royce & Associates LP now owns 1,557,600 shares of the medical instruments supplier’s stock worth $4,050,000 after buying an additional 44,000 shares during the last quarter. Renaissance Technologies LLC boosted its position in Harvard Bioscience by 5.9% in the first quarter. Renaissance Technologies LLC now owns 560,500 shares of the medical instruments supplier’s stock worth $1,457,000 after buying an additional 31,300 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Harvard Bioscience by 1.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,631,348 shares of the medical instruments supplier’s stock worth $4,242,000 after buying an additional 20,499 shares during the last quarter. Institutional investors own 62.19% of the company’s stock.

Harvard Bioscience, Inc. (HBIO) opened at 3.05 on Friday. Harvard Bioscience, Inc. has a 12-month low of $2.25 and a 12-month high of $3.30. The company’s 50-day moving average price is $2.68 and its 200-day moving average price is $2.66. The stock’s market cap is $106.25 million.

Harvard Bioscience (NASDAQ:HBIO) last issued its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by $0.02. The business had revenue of $25.21 million during the quarter, compared to analysts’ expectations of $24 million. Harvard Bioscience had a positive return on equity of 1.45% and a negative net margin of 4.37%. On average, equities analysts expect that Harvard Bioscience, Inc. will post $0.13 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.dailypolitical.com/2017/08/12/algert-global-llc-has-290000-stake-in-harvard-bioscience-inc-hbio.html.

A number of equities analysts recently issued reports on HBIO shares. Zacks Investment Research upgraded Harvard Bioscience from a “sell” rating to a “hold” rating in a report on Friday, April 28th. ValuEngine cut Harvard Bioscience from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. Finally, TheStreet upgraded Harvard Bioscience from a “d+” rating to a “c-” rating in a report on Monday, July 31st. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Harvard Bioscience has a consensus rating of “Buy” and an average target price of $4.75.

In other Harvard Bioscience news, CEO Jeffrey Duchemin acquired 22,000 shares of the stock in a transaction that occurred on Monday, June 12th. The stock was bought at an average cost of $2.76 per share, for a total transaction of $60,720.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Earl R. Lewis acquired 12,238 shares of the stock in a transaction that occurred on Thursday, May 25th. The stock was acquired at an average price of $2.35 per share, with a total value of $28,759.30. The disclosure for this purchase can be found here. Insiders purchased 52,950 shares of company stock valued at $135,275 over the last quarter. 8.80% of the stock is currently owned by company insiders.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

Want to see what other hedge funds are holding HBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harvard Bioscience, Inc. (NASDAQ:HBIO).

Institutional Ownership by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.